Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.52)
# 827
Out of 4,784 analysts
151
Total ratings
44.52%
Success rate
5.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $29.71 | +68.29% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $6.50 | +92.31% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $67.61 | +39.03% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $7.85 | +154.78% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $122.92 | +76.54% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $5.58 | +43.37% | 11 | Mar 7, 2025 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $21 | $8.01 | +162.17% | 16 | Mar 4, 2025 | |
| PCRX Pacira BioSciences | Maintains: Buy | $57 → $70 | $24.91 | +181.01% | 19 | Feb 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $51.74 | +41.09% | 9 | Feb 26, 2025 | |
| GRCE Grace Therapeutics | Reiterates: Buy | $12 | $2.32 | +417.24% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.43 | - | 11 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.15 | - | 13 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $5.03 | +49.11% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $1.00 | +700.00% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $3.28 | +1,714.02% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $1.70 | +11,547.06% | 2 | May 7, 2021 |
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $29.71
Upside: +68.29%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $6.50
Upside: +92.31%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $67.61
Upside: +39.03%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $7.85
Upside: +154.78%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $122.92
Upside: +76.54%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $5.58
Upside: +43.37%
Avadel Pharmaceuticals
Mar 4, 2025
Reiterates: Buy
Price Target: $21
Current: $8.01
Upside: +162.17%
Pacira BioSciences
Feb 28, 2025
Maintains: Buy
Price Target: $57 → $70
Current: $24.91
Upside: +181.01%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $51.74
Upside: +41.09%
Grace Therapeutics
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $2.32
Upside: +417.24%
Nov 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Jun 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.15
Upside: -
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $5.03
Upside: +49.11%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $1.00
Upside: +700.00%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $3.28
Upside: +1,714.02%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $1.70
Upside: +11,547.06%